Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 30% over the past month. The stock hit a new 52-week high of $13.52 in the previous session. Adaptive Biotechnologies has gained 122% since the start of the year compared to the -2.8% gain for the Zacks Medical sector and the 2.7% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on August 5, 2025, Adaptive Biotechnologies reported EPS of -$0.17 versus consensus estimate of -$0.24 while it beat the consensus revenue estimate by 18.47%.For the current fiscal year, Adaptive Biotechnologies is expected to post earnings of -$0.71 per share on $234.4 in revenues. This represents a 34.26% change in EPS on a 30.98% change in revenues. For the next fiscal year, the company is expected to earn -$0.6 per share on $269.94 in revenues. This represents a year-over-year change of 16.55% and 15.16%, respectively.Valuation MetricsThough Adaptive Biotechnologies has recently hit a 52-week high, what is next for Adaptive Biotechnologies? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.Adaptive Biotechnologies has a Value Score of F. The stock's Growth and Momentum Scores are A and A, respectively, giving the company a VGM Score of B.Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Adaptive Biotechnologies currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Adaptive Biotechnologies fits the bill. Thus, it seems as though Adaptive Biotechnologies shares could still be poised for more gains ahead.How Does ADPT Stack Up to the Competition?Shares of ADPT have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is ANI Pharmaceuticals, Inc. (ANIP). ANIP has a Zacks Rank of #1 (Strong Buy) and a Value Score of B, a Growth Score of A, and a Momentum Score of A.Earnings were strong last quarter. ANI Pharmaceuticals, Inc. beat our consensus estimate by 30.43%, and for the current fiscal year, ANIP is expected to post earnings of $7.25 per share on revenue of $840.7 million.Shares of ANI Pharmaceuticals, Inc. have gained 46.1% over the past month, and currently trade at a forward P/E of 12.76X and a P/CF of 12.18X.The Medical - Biomedical and Genetics industry is in the top 41% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ADPT and ANIP, even beyond their own solid fundamental situation.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks